Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DOXYCYCLINE vs KEPIVANCE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex. It also exhibits anti-inflammatory and anti-collagenase activities.
Kepivance (palifermin) is a recombinant human keratinocyte growth factor (KGF) that binds to the KGF receptor, a splice variant of fibroblast growth factor receptor 2 (FGFR2b), stimulating proliferation, differentiation, and migration of epithelial cells, including those in the gastrointestinal tract.
Empiric treatment of acute bacterial exacerbations of COPD,Community-acquired pneumonia,Prostatitis caused by Chlamydia trachomatis,Treatment of Lyme disease,Treatment of Rocky Mountain spotted fever,Acne vulgaris (off-label),Malaria prophylaxis (off-label)
FDA-approved: To decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support.,Off-label: Prevention of oral mucositis in other cancers; management of acute radiation-induced mucositis.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg every 12 hours or 50 mg every 6 hours.
60 mcg/kg/day intravenously for 3 consecutive days before and 3 consecutive days after myelotoxic therapy.
Terminal elimination half-life is 18–24 hours in patients with normal renal function; prolonged to 20–30 hours in renal impairment; allows once or twice daily dosing.
Terminal elimination half-life is approximately 4.5 hours in healthy adults. In patients with renal impairment (Cr Cl <30 m L/min), half-life is prolonged up to 2-fold, requiring dose adjustment. The half-life supports once-daily dosing for 3 consecutive days before chemotherapy.
Doxycycline is partially metabolized in the liver via unspecified pathways; it is not significantly metabolized by CYP450 enzymes. Approximately 40% is excreted renally as active drug.
Metabolized via proteolytic degradation; no specific CYP450 involvement.
Renal (40%) and fecal/biliary (60%); undergoes enterohepatic circulation; active drug and metabolites excreted in urine and feces.
Primarily renal; approximately 90% of the dose is excreted unchanged in urine within 24 hours via glomerular filtration and tubular secretion. Minimal biliary/fecal elimination (<5%).
80–93% bound to plasma proteins, primarily albumin.
Approximately 95% bound to plasma proteins, primarily albumin.
0.75–1.3 L/kg, indicating extensive tissue penetration; high concentrations in lung, liver, bone, and prostate.
Volume of distribution at steady state (Vd_ss) is approximately 0.2 L/kg, indicating limited extravascular distribution, consistent with a large protein-bound molecule. Does not distribute extensively into tissues.
Oral: 90–100% (well absorbed); IV: 100%; topical: minimal systemic absorption (<10%).
Subcutaneous administration: Absolute bioavailability is approximately 90% compared to intravenous administration. Not available orally; only given subcutaneously.
For Cr Cl < 50 m L/min: no dosage adjustment required for most indications; for severe infections or prolonged use, consider monitoring renal function. In patients with Cr Cl < 10 m L/min, reduce dose or avoid if possible due to potential anti-anabolic effect.
No dose adjustment is recommended for renal impairment, but monitor serum creatinine.
Child-Pugh A: no adjustment. Child-Pugh B: use with caution; no specific dose reduction recommended. Child-Pugh C: avoid use due to lack of safety data.
No specific dose adjustment for Child-Pugh class A or B; use caution in severe impairment.
For children >8 years and weighing ≤45 kg: 2.2 mg/kg every 12 hours on day 1, then 2.2 mg/kg once daily or 1.1 mg/kg every 12 hours. For children >45 kg: same as adult. For children <8 years: contraindicated due to risk of permanent tooth discoloration and enamel hypoplasia.
Safety and efficacy not established; no recommended pediatric dose.
No specific dose adjustment required; use standard adult dosing. Monitor renal function and consider potential increased risk of photosensitivity reactions. Avoid in elderly with impaired renal function if alternative agents available.
No specific dose adjustment, but consider age-related renal and hepatic function decline.
There is no FDA black box warning for doxycycline.
None.
Photosensitivity: avoid prolonged sun exposure,Esophageal injury: take with adequate fluids,Hepatotoxicity: caution in hepatic impairment,Intracranial hypertension: risk of pseudotumor cerebri,Delay in bone growth and tooth discoloration in children <8 years,C. difficile-associated diarrhea,Superinfection with resistant organisms
Potential for stimulation of epithelial tumor growth (use caution in patients with non-hematologic malignancies).,Risk of allergic reactions including anaphylaxis.,May cause oral mucosal thickening and dental abnormalities.,Avoid use within 24 hours before or after myelotoxic chemotherapy.
Hypersensitivity to tetracyclines,Children <8 years of age (except for anthrax or severe infections),Pregnancy (especially second and third trimesters)
Hypersensitivity to palifermin or any excipients.,Concurrent use within 24 hours of myelotoxic chemotherapy.
Dairy products (milk, cheese, yogurt), calcium-fortified foods, antacids containing aluminum, calcium, magnesium, and iron supplements can chelate doxycycline, reducing absorption. Separate intake by at least 2 hours. Alcohol is not known to interact significantly. Avoid taking with high-iron foods like spinach or red meat within 2 hours.
No specific food interactions have been reported for KEPIVANCE. Maintain adequate nutrition and hydration as recommended by your healthcare provider.
Category D. Avoid in pregnancy. Risk of fetal harm including permanent tooth discoloration and impaired bone growth when used in second and third trimesters. First trimester use associated with neural tube defects, cardiovascular malformations, and spontaneous abortion. Hepatic necrosis in pregnant women reported.
KEPIVANCE (palifermin) is a recombinant human keratinocyte growth factor. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, palifermin was not teratogenic in rats or rabbits at doses up to 100 mg/kg/day (IV), which produced exposures approximately 40 and 80 times the human exposure at the recommended clinical dose of 60 mcg/kg/day, based on AUC. However, there are no human data. Risk in first trimester: unknown; second and third trimesters: unknown.
Doxycycline is excreted into breast milk in low concentrations (M/P ratio ~0.2-0.6). Theoretical risk of dental staining and bone growth suppression in nursing infants. American Academy of Pediatrics considers compatible with breastfeeding due to low absorption, but alternative antibiotics preferred.
It is not known whether palifermin is excreted in human milk. No data on M/P ratio. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from palifermin, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Increased renal clearance and volume of distribution during pregnancy may reduce serum concentrations, but no dose adjustment recommended due to teratogenicity. Use only if absolutely necessary with caution.
No pharmacokinetic data in pregnancy. No dose adjustment recommendations are provided for pregnancy; use only if clearly needed.
Administer with a full glass of water to reduce esophageal irritation; avoid lying down for 30 minutes after dosing. Tetracyclines bind calcium, so avoid dairy, antacids, and iron within 2 hours of dosing. Use sun protection due to photosensitivity. In children under 8, pregnant, or breastfeeding, avoid due to tooth discoloration and bone growth inhibition. Monitor for superinfection, especially Clostridioides difficile. Dose adjustment not needed in renal impairment but caution in hepatic impairment.
KEPIVANCE (palifermin) is a recombinant human keratinocyte growth factor used to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies undergoing myelotoxic therapy requiring hematopoietic stem cell support. Administer as a 3-day course of 60 mcg/kg/day IV bolus for 3 consecutive days before and 3 consecutive days after myelotoxic therapy. Must be given at least 24 hours before and after chemotherapy; do not administer within 24 hours of chemotherapy due to risk of enhanced cytotoxicity. Monitor for skin reactions, oral/perioral edema, and taste alteration. Contraindicated in patients with known hypersensitivity to E. coli-derived proteins.
Take exactly as prescribed; finish the full course even if you feel better.,Take with a full glass of water and remain upright for 30 minutes after.,Avoid dairy products, antacids, calcium supplements, iron, and magnesium within 2 hours of taking doxycycline.,Use sunscreen and protective clothing; avoid prolonged sun exposure as it can cause severe sunburn.,Do not take if pregnant, breastfeeding, or if you have a child under 8 years old.,Report any signs of severe diarrhea, skin rash, or difficulty swallowing to your doctor.,Store at room temperature away from moisture and heat; do not use outdated medication.
KEPIVANCE reduces the severity and duration of mouth sores caused by high-dose chemotherapy.,It is given as a short intravenous infusion once daily for 3 days before and 3 days after your chemotherapy.,You may experience swelling of the mouth, tongue, or lips; skin rash; or changes in taste. Report these to your healthcare team.,Do not receive KEPIVANCE within 24 hours before or after chemotherapy.,Inform your doctor if you have any allergies, especially to E. coli-derived products.
"Hydrocortisone, a corticosteroid, may inhibit the hepatic metabolism of doxycycline, a tetracycline antibiotic, leading to increased doxycycline plasma concentrations. This elevation can potentiate doxycycline's adverse effects, such as gastrointestinal disturbance, photosensitivity, and hepatotoxicity. Clinically, this interaction may reduce the therapeutic window of doxycycline, requiring dose adjustment or alternative therapy selection."
"Ketobemidone, an opioid analgesic, may inhibit the cytochrome P450 enzyme CYP3A4, which is involved in the metabolism of doxycycline. This can lead to reduced clearance and increased plasma concentrations of doxycycline, potentially enhancing its antibiotic effects or increasing the risk of adverse effects such as photosensitivity, gastrointestinal disturbances, or hepatic toxicity."
"Clobazam, a benzodiazepine and CYP3A4 inducer, may increase the metabolism of doxycycline, a tetracycline antibiotic, reducing its plasma concentration and potentially compromising its antibacterial efficacy. This interaction could lead to subtherapeutic doxycycline levels, increasing the risk of treatment failure or microbial resistance. Conversely, doxycycline may inhibit CYP3A4, potentially elevating clobazam concentrations, though the clinical significance of this effect is less clear."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DOXYCYCLINE vs KEPIVANCE, answered by our medical review team.
DOXYCYCLINE is a Tetracycline Antibiotic that works by Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex. It also exhibits anti-inflammatory and anti-collagenase activities.. KEPIVANCE is a Growth Factor that works by Kepivance (palifermin) is a recombinant human keratinocyte growth factor (KGF) that binds to the KGF receptor, a splice variant of fibroblast growth factor receptor 2 (FGFR2b), stimulating proliferation, differentiation, and migration of epithelial cells, including those in the gastrointestinal tract.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DOXYCYCLINE and KEPIVANCE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DOXYCYCLINE is: 100 mg orally or intravenously every 12 hours on day 1, then 100 mg every 12 hours or 50 mg every 6 hours.. The standard adult dose of KEPIVANCE is: 60 mcg/kg/day intravenously for 3 consecutive days before and 3 consecutive days after myelotoxic therapy.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DOXYCYCLINE and KEPIVANCE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DOXYCYCLINE is classified as Category D/X. Category D. Avoid in pregnancy. Risk of fetal harm including permanent tooth discoloration and impaired bone growth when used in second and third trimesters. First trimester use as. KEPIVANCE is classified as Category C. KEPIVANCE (palifermin) is a recombinant human keratinocyte growth factor. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, palifermin was . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.